A Study to Evaluate the Safety and Efficacy of Aprepitant (MK0869) for Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients

Chemotherapy-Induced Nausea and Vomiting Clinical Trial

Official title:

A Study to Evaluate the Safety and Efficacy of Aprepitant (MK0869) for Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01757210
• Other study ID #: 24267
• Status: Completed
• Phase: N/A
• First received: September 27, 2012
• Last updated: August 21, 2013
• Start date: September 2012
• Est. completion date: August 2013

Study information

• Verified date: August 2013
• Source: West Virginia University Healthcare
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

Aprepitant was approved in 2003. The drug works to lessen the amount of nausea and vomiting that cancer patients experience after treatment. Aprepitant has been well-studied in adults, but not in children. Data from adult studies has shown aprepitant to be safe. It has also been shown to be effective in lessening the amount of nausea and vomiting that adult patients experience. Because aprepitant has been shown to be safe and effective, the investigators have been using it in pediatric patients at this hospital as standard of care. The investigators will be surveying patients already receiving aprepitant for prevention of chemotherapy-induced nausea and vomiting to determine the amount of nausea and vomiting they experience. The investigators will also be surveying these patients to determine what their appetite is like and if they experience any disruptions in activities of daily living. The investigators are also going to be assessing any side effects these patients experience from receiving aprepitant.

Description:

This will be a prospective, observational study conducted at WVU Children´s Hospital. The study will be conducted over a one—year period until data from 20—40 patient encounters is obtained. There will be no randomization and no control group. Information will be collected from all patients who meet the study´s inclusion criteria. Patients will be given a survey to complete at baseline, on all days of chemotherapy, and for five days after the conclusion of chemotherapy using the BARF Scale and a 4—point Likert scale. The information collected from the survey will include the incidence and severity of nausea and emesis, evaluation of appetite, activities of daily living, and rescue medications used for acute CINV. The specific chemotherapy regimen that each patient receives will be recorded. Any data identifying the patient will be de—identified after all pertinent data is collected. Descriptive statistics will be used to analyze data.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: August 2013
• Est. primary completion date: August 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 1 Year to 17 Years

Eligibility

Inclusion Criteria:

1. Patient is between the ages of 1-17 years

2. Patient has a confirmed malignancy

3. Patient is receiving highly or moderately emetogenic chemotherapy

4. Receiving aprepitant as part of an anti-emetic regimen

5. Patient's legally-authorized representative understands and voluntarily signs the written informed consent prior to any study-specific procedures. A copy of the signed informed consent form will be retained by the treating institution.

6. Patient =7 years of age understands and voluntarily signs the written informed assent form prior to any study specific procedures. A copy of the signed informed assent form will be retained by the treating institution.

Exclusion criteria:

1. Pregnant or breast feeding

2. Concomitant use of pimozide, terfenadine, astemizole, or cisapride

3. Child-Pugh score > 9

4. Receiving IV fosaprepitant

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Related Conditions & MeSH terms

• Chemotherapy-Induced Nausea and Vomiting
• Nausea
• Vomiting

Locations

Country	Name	City	State
United States	WVU Healthcare	Morgantown	West Virginia

Sponsors (1)

Lead Sponsor	Collaborator
West Virginia University Healthcare

Country where clinical trial is conducted

United States, 

References & Publications (3)

Choi MR, Jiles C, Seibel NL. Aprepitant use in children, adolescents, and young adults for the control of chemotherapy-induced nausea and vomiting (CINV). J Pediatr Hematol Oncol. 2010 Oct;32(7):e268-71. doi: 10.1097/MPH.0b013e3181e5e1af. — View Citation

Gore L, Chawla S, Petrilli A, Hemenway M, Schissel D, Chua V, Carides AD, Taylor A, Devandry S, Valentine J, Evans JK, Oxenius B; Adolescent Aprepitant in Cancer Study Group. Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea — View Citation

Smith AR, Repka TL, Weigel BJ. Aprepitant for the control of chemotherapy induced nausea and vomiting in adolescents. Pediatr Blood Cancer. 2005 Nov;45(6):857-60. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of episodes of nausea and vomiting	The primary outcome measure is assessing the incidence of chemotherapy-induced nausea and vomiting in pediatric patients receiving highly or moderately emetogenic chemotherapy and a prophylactic regimen that includes aprepitant. The incidence of chemotherapy-induced nausea and vomiting will be evaluated using the BARF Scale and a 4-point Likert scale on all days of chemotherapy and for five days following the conclusion of chemotherapy compared to baseline	Five days after end of chemotherapy	No
Secondary	Appetite score on a 4-point Likert scale	Patients will be assessed for changes in appetite using a 4-point Likert scale at baseline, on all days of chemotherapy, and for the five days following the conclusion of chemotherapy	Five days after the end of chemotherapy	No
Secondary	Activities of daily living score on a 4-point Likert scale	Patients will be assessed for changes in activities of daily living using a 4-point Likert scale at baseline, on all days of chemotherapy, and for five days following the conclusion of chemotherapy	Five days after the end of chemotherapy	No
Secondary	Number of medications used for breakthrough nausea and vomiting	The usage of all breakthrough medications for chemotherapy-induced nausea and vomiting while in the hospital will be recorded.	Five days after the end of chemotherapy	No
Secondary	Participants with Adverse Events as a Measure of Safety and Tolerability	Incidence of adverse events that can be definitely or probably related to aprepitant using the Naranjo Adverse Event Scale.	Five days after the end of chemotherapy	No